Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Whole-cell Bordetella pertussis refers to chemically or physically inactivated suspensions of the bacterium used in vaccines to prevent whooping cough. Inactivation, typically with formalin or beta-propiolactone, renders the bacteria non-infectious while retaining antigenic properties necessary to induce protective immunity. While effective, whole-cell vaccines are associated with higher rates of adverse reactions compared to acellular vaccines.
Inactivated bacteria stimulate antibody production and cellular immunity against B. pertussis antigens.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bordetella pertussis Bacteria (Whole Cell) (B. pertussis (whole cell)).